TCM
ESPR

Towercrest Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Towercrest Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8,500
Closed -$268K – 80
2020
Q1 		$268K Buy
+8,500
New +$449K 0.08% 68

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Towercrest Capital Management's ESPR Position: Q2 2020 in Review

Towercrest Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2020, closing a stake of 8,500 shares — an estimated $268K sold.

Towercrest Capital Management first reported a position in ESPR in Q1 2020 and held it in 1 quarter. The position peaked at $268K in Q1 2020. 182 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

  • Towercrest Capital Management reported no remaining Esperion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Towercrest Capital Management sold 8,500 Esperion Therapeutics shares in Q2 2020, an estimated $268K.
  • Towercrest Capital Management first reported a position in Esperion Therapeutics in Q1 2020 and held it in 1 quarter.
  • Towercrest Capital Management's Esperion Therapeutics position peaked at $268K in Q1 2020.
  • 182 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on Towercrest Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.